Abstract:Objective: This study aimed to evaluate the efficacy and safety of the Meifute (R) antifungal solution on moccasin-type tinea pedis with optimal application time. Methods: A multicentered, randomized and open clinical trial was conducted by enrolling 267 patients with moccasin-type tinea pedis from 10 centers. 91 of these patients were treated with regimen A (foot bath twice per 7 days, 2 hours each time), 87 with regimen B (foot bath twice per 7 days, 1 hour each time) and 89 with regimen C (foot bath twice per 7 days, 0.5 hour each time). The evaluation of mycological effect, clinical efficacy and the overall therapeutic effect were achieved using fungus microscopic examination, fungus culture method and total symptom score. The initial valuation data were recorded as the baseline and further data were collected 1 week after the first administration (V1), 1 week after the second administration (V2) and 2 weeks after the withdrawal (V3). Results: At V3, the number of eligible patients in group A, B and C were 69, 78 and 80, respectively. There was no statistically significant difference in the fungal clearance rates (84.1%, 88.5% and 76.3%, respectively), clinical effective rate (14.5%, 28.2% and 24.1%, respectively) or integral effective rate (49.3%, 61.5% and 56.3%, respectively) among three groups. The adverse events including transient pain (31 cases, 11.6%), pain (20 cases, 7.5%), erosion (17 cases, 6.4%), pruritus (10 cases, 3.7%), burning (6 cases, 2.2%) and swelling (3 cases, 1.1%) be alleviated without any treatment. The incidence of pain and erosion in group A was significantly higher than that in group B and C. The only case of ulcer happened in group A which was cured after one-week application of Bactroban, Bifonazole, and Hirudoid. Because of the different incident of adverse reactions, there were significant difference in the dropout rates among group A, B and C (9.9%, 2.3% and 0.0%, respectively). Conclusion: The therapeutic efficacy of a 0.5 h treatment with antifungal liquid was found to be the same as that of standard application time of 2 hours. On the other hand, 0.5 h treatment protocol could reduce the incidence of adverse reactions and therefore improve the compliance of patients.

Treatment of Superficial Mycosis with Compound Bifonazole Solution: A Double-blind Controlled Clinical Trial

Photodynamic Therapy in the Treatment of Superficial Mycoses: An Evidence-based Evaluation

Terbinafine versus itraconazole for treatment of dermatophyte onychomycosis: a meta-analysis

Short-term Oral Terbinafine Combined with Topical Bifonazole Cream Treating Moderate and Severe Tinea Pedis

Clinical observation of 3 antifungal creams in treating the 240 patients with superficial mycoses

Bifonazole -Co Cream in the Treatment of Tinea Cruris and Tinea Corporis:A Randomized Double-blind Vehicle-controlled Clinical Trial

A Long-Term Clinical Study on Oral Terbinafine Combined with Topical Bifonazole Cream for Tinea Pedis Treatment

Observation of clinical efficacy of sporanox combined with bifonazole cream in treatment of tinea pedis

Double-blind Randomized Controlled Clinical Trial of Butenafine Hydrochloride 1% Cream in the Treatment of Tinea Corporis and Cruris and Tinea Pedis

Comparison of 2 Weeks Versus 4 Weeks of Luliconazole 1％ Cream for the Treatment of Tinea Pedis: a Randomized, Double-Blind, Multicenter, Controlled Trial

Evaluation of efficacy and safety of flutrimazole cream 1% in the treatment of tinea pedis

A Multicentered, Randomized, Open Study On Efficacy And Safety Of Meifute (R) Antifungal Solution Of Optimal Application Time In Moccasin-Type Tinea Pedis

Randomized, Investigator-Masked, Controlled, Multicenter Clinical Trial of 0.25% Amorolfine Hydrochloride Cream in the Treatment of Tinea Corporis and Cruris and Tinea Pedis

Multicenter, Double-Blind, Randomized Controlled Sdudy on Sertaconazole 2% Cream and Miconazole 2% Cream in the Treatment of Tinea Pedis and Tinea Corporis and Cruris

Efficacy and Safety of 1 % Terbinafine Film-Forming Solution in Chinese Patients with Tinea Pedis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study

Efficacy of topical terbinafine and clotrimazole in the treatment of dermatophytoses: a Clinical and Microbiological Comparision

Clinical effect observation of itraconazole capsule combined with bifona-zole cream in the treatment of tinea cruris

Compared observation of the therapeutic effect of Terbinafine ointment with that Miconazole ointment in treatment of tinea pedis/manun

Treatment of chromomycosis with terbinafine: preliminary results of an open pilot study

Efficacy and Safety of Amorolfine Lotion 0.25% w/v Compared to Amorolfine Cream 0.25% w/w in Patients With Superficial Fungal Infections of the Skin: A Multi-center, Randomized, Open-Label, Active-Controlled, Non-inferiority Phase III Clinical Trial

Efficacy of terbinafine and itraconazole in different doses and in combination in the treatment of tinea infection: A randomized controlled parallel group open labeled trial with clinico-mycological correlation